[go: up one dir, main page]

WO2008115259A3 - Inhibiteurs d'ubiquitine ligase - Google Patents

Inhibiteurs d'ubiquitine ligase Download PDF

Info

Publication number
WO2008115259A3
WO2008115259A3 PCT/US2007/075511 US2007075511W WO2008115259A3 WO 2008115259 A3 WO2008115259 A3 WO 2008115259A3 US 2007075511 W US2007075511 W US 2007075511W WO 2008115259 A3 WO2008115259 A3 WO 2008115259A3
Authority
WO
WIPO (PCT)
Prior art keywords
ubiquitination
pharmaceutical compositions
compounds
treatment
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/075511
Other languages
English (en)
Other versions
WO2008115259A2 (fr
Inventor
Rajinder Singh
Usha Ramesh
Jianing Huang
Sarkiz D Issakani
Lyuben Tsvetkov
Matthew David Petroski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigel Pharmaceuticals Inc
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of WO2008115259A2 publication Critical patent/WO2008115259A2/fr
Publication of WO2008115259A3 publication Critical patent/WO2008115259A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés et des compositions pharmaceutiques utiles comme inhibiteurs d'agent d'ubiquitine, en particulier des inhibiteurs d'ubiquitine ligase. Les composés et les compositions pharmaceutiques proposés par la présente invention sont utiles en tant qu'inhibiteurs des voies biochimiques d'organismes impliquant une ubiquitine, comme des voies de transduction de signal. L'invention comprend également l'utilisation des composés et des compositions pharmaceutiques de la présente invention dans le traitement d'infections requérant une inhibition d'ubiquitination. De plus, l'invention concerne des procédés d'inhibition d'ubiquitination dans une cellule, incluant la mise en contact d'une cellule dans laquelle une inhibition d'ubiquitination est souhaitée avec un composé ou une composition pharmaceutique proposés par l'invention, en particulier pour inhiber l'activité d'ubiquitine ligase de TRAF 6.
PCT/US2007/075511 2006-08-10 2007-08-08 Inhibiteurs d'ubiquitine ligase Ceased WO2008115259A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82205006P 2006-08-10 2006-08-10
US60/822,050 2006-08-10
US88758507P 2007-01-31 2007-01-31
US60/887,585 2007-01-31

Publications (2)

Publication Number Publication Date
WO2008115259A2 WO2008115259A2 (fr) 2008-09-25
WO2008115259A3 true WO2008115259A3 (fr) 2008-12-18

Family

ID=39708865

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/075511 Ceased WO2008115259A2 (fr) 2006-08-10 2007-08-08 Inhibiteurs d'ubiquitine ligase

Country Status (1)

Country Link
WO (1) WO2008115259A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108658962B (zh) * 2017-03-30 2021-10-01 复旦大学 3-取代香豆素呋咱衍生物及其在制备抗多药耐药肿瘤药物中的用途

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99448C2 (en) 2006-11-27 2012-08-27 Х. Луннбэк А/С Heteroaryl amide derivatives
US12240854B2 (en) 2018-03-22 2025-03-04 Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuergesundheit Und Umwelt (Gmbh) TRAF 6 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002284A1 (fr) * 2004-06-22 2006-01-05 Rigel Pharmaceuticals, Inc. Inhibiteurs de l'ubiquitine ligase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002284A1 (fr) * 2004-06-22 2006-01-05 Rigel Pharmaceuticals, Inc. Inhibiteurs de l'ubiquitine ligase

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108658962B (zh) * 2017-03-30 2021-10-01 复旦大学 3-取代香豆素呋咱衍生物及其在制备抗多药耐药肿瘤药物中的用途

Also Published As

Publication number Publication date
WO2008115259A2 (fr) 2008-09-25

Similar Documents

Publication Publication Date Title
WO2005007621A3 (fr) Inhibiteurs de ligase d'ubiquitine
WO2005037845A8 (fr) Compositions de benzothiazole et de thiazole'5,5-b!pyridine et leur utilisation comme inhibiteurs de l'ubiquitine ligase
WO2008013838A3 (fr) Dérivés de pyridizinone
EP2573069A3 (fr) Inhibiteurs d'histone désacétylase et leurs promédicaments
WO2008055068A3 (fr) Inhibiteurs de l'histone désacétylase
WO2007089634A3 (fr) Inhibiteurs de la synthase d'acides gras (fas)
WO2006113919A3 (fr) Preparation et utilisation de derives de l'acide aryle alkyle dans le traitement de l'obesite
WO2007109178A3 (fr) Dérivés d'indole en tant qu'inhibiteurs de l'histone désacétylase
WO2007097931A3 (fr) Aminotétrahydropyrannes en tant qu'inhibiteurs de dipeptidylpeptidase-iv dans le traitement prophylactique ou thérapeutique du diabète
WO2009097113A3 (fr) Composés oxazole et thiazole utilisés comme modulateurs de la b-caténine et leurs utilisations
WO2007092213A3 (fr) Inhibiteurs d'enzyme d'activation e1
WO2005111039A3 (fr) Composés et procée pour l'inhibition de progression mitotique
WO2008049123A3 (fr) Compositions et procédés pour l'inhibition de la voie jak
WO2008021038A3 (fr) Pyridobenzazépines et méthodes d'inhibition de la progression mitotique
NO20092569L (no) Inhibitorer av Akt-aktivitet
WO2008019124A8 (fr) Composés hétéroaryles utiles comme inhibiteurs des enzymes d'activation e1
WO2007087231A3 (fr) Aminocyclohexanes utiles en tant qu'inhibiteurs de la dipeptidyl peptidase-iv pour traiter ou prévenir le diabète
WO2010009139A3 (fr) Composés inhibiteurs de pyrimidine imidazolyle
WO2008118391A3 (fr) Composés qui modulent l'activité hsp90
WO2006091395A3 (fr) Inhibiteurs d'activite d'akt
WO2006135627A3 (fr) Inhibiteurs de l'activite akt
WO2008033798A3 (fr) Inhibiteur de kinases
WO2010017035A3 (fr) Inhibiteurs d'iap
WO2008061724A3 (fr) Compositions innovantes
WO2007011760A3 (fr) Inhibiteurs de la kinesine mitotique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07874455

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07874455

Country of ref document: EP

Kind code of ref document: A2